Premium
Effective use of fondaparinux in patient with unresponsiveness to nadroparin
Author(s) -
Hartinger Jan Miroslav,
Svobodová Alžběta,
Malíková Ivana,
Šachl Robert,
Slanař Ondřej
Publication year - 2021
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.13328
Subject(s) - fondaparinux , antithrombin , medicine , anticoagulant , heparin , low molecular weight heparin , pharmacology , anesthesia , thrombosis , surgery , venous thromboembolism
What is known and objective Fondaparinux exhibits a similar mechanism of action as LMWH. Since both of these drugs bind to antithrombin and increase its affinity to factor Xa, fondaparinux is not expected to be an effective alternative anticoagulant to LMWH in case of LMWH resistance. Case summary We report on a case of effective anticoagulation using fondaparinux following total unresponsiveness to high doses of nadroparin administered twice daily, as confirmed via repeated anti‐Xa measurements. The antithrombin levels were within the normal range. What is new and conclusion To the best of our knowledge, this is the first report of the effective use of fondaparinux in the case of unresponsiveness to LMWH.